Skip to main content
Midas Edge

Marker Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 18, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 18, 2026

MRKR$0.95-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ · ​ · ​ · ​ ​ ​ · Additional · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Total
​ · ​ · Common Stock · ​ · Paid- · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Par value · ​ ​ ​ · in Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at January 1, 20248,891,420​​8,891​​450,329,515​​(436,285,863)​​14,052,543
Shares purchased pursuant to ATM agreement​8,178​​8​​36,894​​—​​36,902
Issuance of common stock from exercise of stock options​25,602​​25​​62,134​​—​​62,159
Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs of $1.2 million​1,783,805​​1,784​​14,890,469​​—​​14,892,253
Stock-based compensation—​​—​​245,864​​—​​245,864
Net loss—​​—​​—​​(10,731,315)​​(10,731,315)
Balance at December 31, 202410,709,005​​10,708​​465,564,876​​(447,017,178)​​18,558,406
Shares purchased pursuant to ATM agreement​5,358,292​​5,359​​9,858,524​​—​​9,863,883
Issuance of common stock from exercise of prefunded warrants605,830​​605​​—​​—​​605
Stock-based compensation—​​—​​537,540​​—​​537,540
Net loss—​​—​​—​​(12,163,620)​​(12,163,620)
Balance at December 31, 202516,673,127​​16,672​​475,960,940​​(459,180,798)​​16,796,814
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.